UT4 Health Utility Scores in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Response to Stimulant Treatment
Juliana Setyawan(Arena Pharmaceuticals (United States)), David Coghill(The University of Melbourne), Alessandro Zuddas(University of Cagliari), Mats Johnson(Sahlgrenska University Hospital), Ralph Bloomfield(AstraZeneca (United Kingdom)), Tobias Banaschewski(Heidelberg University), P. Hodgkins(Takeda (United States)), Michel Lecendreux(Laboratoire National de Référence)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Computerized Training of Working Memory in Children With ADHD-A Randomized, Controlled Trial
|Journal of the American Academy of Child & Adolescent Psychiatry|2005|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
|Cell|2019|1.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k